|
KMID : 0338420170320040656
|
|
The Korean Journal of Internal Medicine
2017 Volume.32 No. 4 p.656 ~ p.667
|
|
|
Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
|
|
Hong Young-Joon
Jeong Myung-Ho
Bae Jang-Ho
Oh Seok-Kyu
Rha Seung-Woon
Hur Seung-Ho
Lee Sung-Yun
Kim Sang-Wook
Cha Kwang-Soo
Chae In-Ho
Ahn Tae-Hoon
Kim Kee-Sik
|
|
|
Abstract
|
|
|
Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients.
Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month.
Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (?42.05 ± 32.73 mg/dL vs. ?34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (?20.16 ± 54.49 mg/dL in 4 mg group and ?24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (?0.13% ± 1.21% in 4 mg group and ?0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively).
Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
|
|
|
KEYWORD
|
|
|
Myocardial infarction, Atherosclerosis, Lipids, Hydroxymethylglutaryl-CoA reductase inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|